Please login to the form below

Not currently logged in
Email:
Password:

trial failure

This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Pfizer started dosing patients with its mini-dystrophin

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure. ... The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a

  • Summit plunges after Duchenne disappointment Summit plunges after Duchenne disappointment

    Summit plunges after Duchenne disappointment. UK company to abandon lead molecule after phase II trial failure. ... However while this clinical trial failure was once typical of the DMD field, there are signs of a breakthrough against the life-shortening

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    AZ’ s Fasenra hit by COPD trial failure. Results give advantage to respiratory rivals GSK. ... AstraZeneca’s hopes of taking on rival GlaxoSmithKline in the respiratory antibody sector have taken a knock after a failed phase III trial.

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    The failure of Incyte’s IDO1 inhibitor epacadostat in a trial pairing it with Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) last month seems to have started a chain ... The Incyte trial failure was swiftly followed by a decision by NewLink

  • AZ’s immuno-oncology combo fails another lung cancer trial AZ’s immuno-oncology combo fails another lung cancer trial

    AZ’ s immuno-oncology combo fails another lung cancer trial. Latest failure casts doubt on company’s CTLA4 drug. ... achieved a “clinically meaningful reduction in the risk of death compared to chemotherapy”, although the trial wasn’t powered

More from news
Approximately 32 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. “ ... Particularly when we have high failure rates in late stages in clinical

  • Customer valuation in pharma Customer valuation in pharma

    Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Alzheimer's: the numbers we cannot forget

    This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose

  • A forward march for adaptive designs

    For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics